Urgent Evaluation for Endometrial Cancer is Required
Any postmenopausal woman with vaginal bleeding must be urgently referred and evaluated for endometrial cancer, as approximately 10% of these cases will have malignancy 1, 2, 3. The hot flashes, while bothersome, are secondary to the critical need to rule out cancer.
Immediate Diagnostic Workup
First-Line Investigation
The initial evaluation should include:
- Transvaginal ultrasound (TVUS) to measure endometrial thickness
- Endometrial biopsy for histological diagnosis
These two modalities are complementary and together provide safe, cost-effective initial assessment 4, 3. TVUS alone is insufficient because it only provides structural information, while biopsy gives definitive histology 4.
Interpretation of Results
If endometrial thickness is <5mm on TVUS AND the bleeding has stopped AND examination is normal, no further action is needed 3. This threshold has high negative predictive value for endometrial cancer.
If endometrial thickness is ≥5mm OR bleeding persists OR biopsy is negative but symptoms continue, proceed to fractional dilation and curettage (D&C) under anesthesia 1. Office endometrial biopsies have a 10% false-negative rate, making D&C essential in symptomatic patients with negative initial biopsy 1.
Additional Evaluation Components
- Speculum examination: Assess for cervical cancer, polyps, or vaginal atrophy as alternative bleeding sources 3
- Pelvic examination: Evaluate for masses 3
- Chest imaging: Consider chest x-ray as part of cancer staging workup 1
Common Pitfalls to Avoid
Do not dismiss postmenopausal bleeding as "just atrophy" without proper evaluation. While vaginal atrophy is a common benign cause, the 10% cancer risk mandates thorough investigation 2, 3.
Do not rely solely on ultrasound. The combination of TVUS and endometrial biopsy is superior to either alone 4.
Do not accept a single negative office biopsy in a symptomatic patient. The false-negative rate necessitates D&C if bleeding persists 1.
Management of Hot Flashes (Secondary Priority)
Once malignancy is excluded, address the vasomotor symptoms. At age 67, this patient is likely >10 years post-menopause, which places her outside the optimal window for hormone therapy initiation.
Treatment Options
For severe symptoms significantly impacting quality of life, consider:
- Non-hormonal first-line agents: Gabapentin, SSRIs (selective serotonin reuptake inhibitors), or SNRIs (serotonin-norepinephrine reuptake inhibitors) 5
- Short-term low-dose estrogen therapy only if non-hormonal options fail and after thorough cardiovascular risk assessment 5
The evidence suggests that estrogen initiated many years after menopause (as in this 67-year-old) carries excess coronary risk compared to initiation soon after menopause 5. Therefore, non-hormonal options should be exhausted first 5.
Duration Considerations
If hormone therapy is ultimately chosen, limit to 4-5 years maximum due to increasing breast cancer risk with longer duration 5. However, given her age and time since menopause, the risk-benefit ratio strongly favors non-hormonal management 6, 5.
Risk Stratification
Consider screening for Lynch syndrome if endometrial cancer is diagnosed, as this accounts for ~5% of cases and has implications for family members 1. Universal tumor testing for DNA mismatch repair defects (MLH1, MSH2, MSH6) is recommended 1.